
usd pm et
summari among largest gener non-brand pharmaceut firm world produc
broad rang tradit specialti drug global market
nm price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
aug pm stock trade
star recommend
recent chang sell
hold target price
recent chang
highlight section stock report
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra lower
hold drop target
ep estim --
maintain ep estim drop
adjust ep
vs beat consensu
revenu grew yoy led north america
revenu yoy recent
launch wixela yupelri overcom
sustain gener price volum
pressur view low cost
foreign produc gain market share
ytd adjust ep adjust free cash flow
yoy respect
driven foreign competit view
manag tout pend
combin upjohn unit
strategi stabil current declin yet
given upjohn sale current fall
pace yoy see high risk deal
under-perform expect
expect share outperform next
oper typic pharmaceut risk includ
uncertainti stem program
regulatori approv process competitor challeng
patent market share signific legal risk also
exist on-going govern lawsuit
investig relat opioid market alleg
price-fix risk partial off-set divers
portfolio product account
revenu sale come
outsid also think mitig risk
success histori develop high-barri
gener biosmilar
feb ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
chairman board
corpor overview develop licens manufactur market pharmaceut
primarili gener biosimilar varieti therapeut categori estim rank
twelfth among drug produc term total revenu largest -base
gener drug maker top five therapeut area term revenu central nervou system
anesthesia infecti diseas respiratori allergi gastroenterolog diabet
gener least total revenu
compani oper three segment north america gener total revenu
oper incom europ gener revenu oper incom rest
world gener revenu oper incom
market profil reach peak estim gross profit margin gener drug
industri fell nearli eight percentag point driven two key factor first annual fda gener
drug approv grew rapidli allow larg increas number
competitor produc typic gener drug second major retail pharmaci chain drug
wholesal band togeth purchas joint ventur increas negoti power gener
gener price declin due intens competit increas scale custom think
long-term trajectori volum growth posit industri experi two import
demand driver next five ten year includ rapid age develop popul
prime prescript util year particularli estim babi boomer turn
day rapidli expand middl class gain first-tim access advanc health
care pharmaceut emerg market nation like india china
corpor strategi mani gener drug maker equip target small-molecul brand
drug low barrier product thin margin exampl nine
compet gener viagra brand tablet fifteen differ gener lipitor brand tablet
unlik mani peer mostli produc simpler commodity-lik gener shift
busi toward large-molecul specialti drug biosimilar higher barrier entri due
complex regulatori approv manufactur requir estim commodity-lik
gener gener mylan gener sale amount fall
around compani ramp import new complex gener biosimilar
exampl recent success complex drug area includ gener copaxon inject
multipl sclerosi drug fda approv fulphila biosimilar neulasta anti-infect
inject cancer patient fda approv wixela inhub gener inhal asthma
brand advair fda approv multi-billion-dollar brand drug gener
biosimilar compet one gener provid greater valu crowd
commodity-lik gener space think compani robust pipelin continu complex drug
major transact announc plan spin off-pat brand
drug busi upjohn asset yet unnam new compani newco expect
close upjohn sell mani well-known drug like viagra lipitor major growth
driver declin lose patent protect sharehold
newco whose pro-forma free cash flow around mean stake
think good deal better would earn view
given year-end june trend downward yoy
upjohn deal also increas resourc help manag alleg price-fix opioid litig risk
well drive greater scale help battl on-going market share loss lower-cost india-bas
competit view
legal risk current subject numer investig lawsuit
govern competitor case sometim result larg legal legal liabil may
meaning impact abil make long-term invest sustain growth
pharmaceut busi inform relat case often becom public unexpectedli
creat bout prolong neg sentiment equiti valuat compress march
compani defend number high profil case includ limit follow
name along numer drug manufactur distributor case relat
nation opioid crisi brought multipl government entiti along
gener maker su multipl state allegedli engag wide-spread gener price
fix illegel market share alloc also name defend class action suit
relat price market epipen auto-injector
financi trend sale aid sever acquisit rose billion billion
repres three-year compound annual growth rate compound-annual-growth-rate howev sale fell
versu advers impact sever gener drug price deflat due intens
competit consolid downstream custom adjust pre-tax incom per share grew
declin repres three-year compound-annual-growth-rate
despit challeng environ gener drug maker recent year leverag
maintain safe though conserv level view ebita-to-interest
materi better peer-averag around
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
fairli valu
neutral sinc octob technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
slowdown novel drug approv
potenti new price regul
neg partial off-set upcom
favor period patent expir
also expect major gener maker continu
struggl lower cost foreign competit
keep pressur profit margin
banner year new brand
drug fda see slowdown
total novel drug
approv fda
signific surg compar approv
new brand help drive
ebitda growth sub-industri
versu averag
new drug launch appear
slow howev
approv year august
period also observ
yoy declin spend
like portend effort maintain margin
sluggish revenu growth year ahead
pharmaceut also face increas risk
new drug price rule view
accord wall street journal studi
govern health system develop
countri like england norway canada
often pay less major drug
poll indic american feel drug
cost unreason believ
dynam increas pressur drug
maker curtail price hike politician
enact polici lower drug cost
voter accordingli sever new propos
lower drug price emerg side
isl recent month trump
administr announc explor base
medicar drug price intern index
hous democrat introduc bill
would allow medicar directli negoti
price drug maker senat
republican propos lower
out-of-pocket maximum medicar drug
plan shift cost burden
drug maker none propos
current enough support becom law
view see polit parti
increas focu control drug cost
signific risk weigh outlook
sub-industri
balanc neg factor face
brand drug maker expect
upcom favor period patent
expir typic biggest
revenu headwind base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
major gener maker neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
estim india-bas produc oper
averag gross margin
versu top western gener
foreign firm
drop broader composit
year-to-d septemb
pharmaceut index
gain
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra maintain strong buy opinion share
lower target price ep estim --
histor forward price-to-earnings averag due intens price pressur
gener drug drop ep estim
ep vs beat consensu revenu declin
yoy north america sale total europ fall
yoy respect due rapidly-grow sale new complex gener
biosimilar fail off-set declin commodity-lik gener rest world
sale total grew yoy strong growth china sale
growth well expect still think revenu increas
vs strong ramp gener advair biosimilar neulasta
sever new launch continu think share
attract valu low end guidanc repres yield
current market cap growth expect long-term /colin scarola
pm et cfra rais sector overweight
marketweight cfra rais
sector overweight marketweight market valuat
expand sector trade discount histor averag cfra
find opportun within health care sector trade forward
price-to-earnings basi histor averag first quarter
compani health care sector beat sale
earn estim best perform index biotech
pharmaceut compani account market capit
sector drug pipelin approv time reduct activ make
industri attract care histori outperform
season slow period year may octob cfra
forecast sector like disappoint lindsey bell
analyst research note compani news
et cfra lower opinion share sell hold
drop target ep estim --
histor forward price-to-earnings averag maintain ep estim
drop adjust ep vs beat
consensu revenu grew yoy led north america
revenu yoy recent launch wixela yupelri overcom
sustain gener price volum pressur view low
cost foreign produc gain market share despit roughli flat
revenu ytd thru ytd adjust ep adjust free cash flow
yoy respect driven foreign competit
view manag tout pend combin upjohn unit
strategi stabil current declin yet given upjohn sale
current fall pace yoy see high risk deal
under-perform expect expect share outperform
et cfra lower opinion share hold buy
keep target ep estim
unchang histor forward price-to-earnings averag due signific
litig risk competit lower-cost indian drug maker today
announc plan spin off-pat brand drug
busi upjohn asset yet unnam new compani
sharehold newco whose pro-forma free cash flow
around mean stake think well
deal better would earn
view given trail year downward trend
deal also increas resourc manag alleg price-fix litig risk
on-going market share loss india-bas competit view given
magnitud risk howev think long-term growth opportun
limit see share near fair valu adjust recommend
pm et cfra lower opinion share buy strong
buy drop price target ep
estim maintain -- histor forward price-to-earnings averag
due mount litig risk share sinc may
expans anti-trust case alleg wide-spread price fix
among gener maker estim gener annual sale
alleg price-fix drug year question
potenti liabil case highli uncertain could signific
downgrad reflect view price-to-earnings multipl remain compress
prolong neg sentiment stem high degre legal
uncertainti could take year resolv despit litig
overhang keep hold think share like
oversold follow news liabil ultim prove
manag due ampl free cash flow gener strong ramp sever
first-to-fil gener biosimilar /colin scarola
pm et cfra maintain opinion share gener drug maker
share firm involv gener drug includ teva
sharpli today follow
expans anti-trust lawsuit three firm subsidiari
alreadi name one defend relat on-going case origin
alleg illeg price fix drug may file
expand alleg defend firm involv mani drug
teva gener state claim without merit
plan defend alleg present materi risk
gener maker think risk much today
last week alleg relat case alreadi
underway sever year process like take sever year
conclus forward price-to-earnings multipl alreadi
long-term averag last week think risk alreadi price
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
